Participated in Vima Therapeutics' $60M Series A alongside Atlas Ventures and Access Industries. Vima is developing the first oral therapy for dystonia and related movement disorders.
Vima Therapeutics is a clinical-stage biotechnology company pioneering a new era in the treatment of dystonia and related movement disorders
Vima Therapeutics is a clinical-stage biotechnology company pioneering a new era in the treatment of dystonia and related movement disorders. We are advancing VIM0423, a potential first-in-class oral therapy for dystonia and Parkinson's disease, with the goal of helping individuals regain control of their movements by targeting the underlying biology.